Journal
ACS APPLIED MATERIALS & INTERFACES
Volume 10, Issue 8, Pages 6904-6916Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsami.7b18525
Keywords
nitric oxide-delivering; high-density lipoprotein-like nanoparticles; biomimetic; nanotherapy; vascular disease; S-nitrosylation
Funding
- NTU-NU Institute for Nanomedicine
- NIH/NHLBI [BRP 5R01HL116577, T32HL094293]
- NIH [R01CA167041]
- CRN Regenerative Nanomedicine Catalyst Award Program at the Northwestern University
- Simpson Querrey Institute for BioNanotechnology
- Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource [NSF NNCI-1542205]
- MRSEC program at the Materials Research Center [NSF DMR-1121262]
- International Institute for Nanotechnology (TIN)
- Keck Foundation
- State of Illinois, through the IIN
- U.S. Army Research Office
- U.S. Army Medical Research and Material Command
- Northwestern University
- NCI CCSG [P30 CA060553]
Ask authors/readers for more resources
Disorders of blood vessels cause a range of severe health problems. As a powerful vasodilator and cellular second messenger, nitric oxide (NO) is known to have beneficial vascular functions. However, NO typically has a short half-life and is not specifically targeted. On the other hand, high-density lipoproteins (HDLs) are targeted natural nanoparticles (NPs) that transport cholesterol in the systemic circulation and whose protective effects in vascular homeo-stasis overlap with those of NO. Evolving the AuNP-templated HDL-like nanoparticles (HDL NPs), a platform of bioinspired HDL, we set up a targeted biomimetic nanotherapy for vascular disease that combines the functions of NO and HDL. A synthetic S-nitrosylated (SNO) phospholipid (1,2-dipalmitoyl-sn-glycero-3-phosphonitrosothioethanol) was synthesized and assembled with S-containing phospholipids and the principal protein of HDL, apolipoprotein A-I, to construct NO-delivering HDL-like particles (SNO HDL NPs). SNO HDL NPs self-assemble under mild conditions similar to natural processes, avoiding the complex postassembly modification needed for most synthetic NO-release nanoparticles. In vitro data demonstrate that the SNO HDL NPs merge the functional properties of NO and HDL into a targeted nanocarrier. Also, SNO HDL NPs were demonstrated to reduce ischemia/reperfusion injury in vivo in a mouse kidney transplant model and atherosclerotic plaque burden in a mouse model of atherosclerosis. Thus, the synthesis of SNO HDL NPs provides not only a bioinspired nanotherapy for vascular disease but also a foundation to construct diversified multifunctional platforms based on HDL NPs in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available